Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/ISTURISA 5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

ISTURISA 5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA

Recordati Rare Diseases🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 12, 2021
Approval ID: 6ad952a41c5ff5bc
Company: Recordati Rare Diseases
Type: Standard

Approval Details

Approval Id: 6ad952a41c5ff5bc
Drug Cima Aemps Name: ISTURISA 5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 1171409002
Holder Company Name: Recordati Rare Diseases
Marketing Company Name: Recordati Rare Diseases Spain, S.L.U.
Holder Company Detail Path: /organization/recordati-rare-diseases
Authorization Date: 2021-02-12
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Recordati Rare Diseases
Company Detail Path: /organization/recordati-rare-diseases

Company Information

Pharmaceutical Company Name: RECORDATI RARE DISEASES
Country Name: France
City Name: puteaux,ile de france,country_fr
Address: IMMEUBLE LE WILSON IMM LE WILSON 1
Website: https://www.recordatirarediseases.com

Active Ingredients

OSILODROSTAT FOSFATO

7,155 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 12, 2021

Approval ID

6ad952a41c5ff5bc

Type

Standard

Back to CIMA-AEMPS Approvals

ISTURISA 5 mg COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details